Shareholders Are Raving About How The BioTelemetry (NASDAQ:BEAT) Share Price Increased 601%

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

While BioTelemetry, Inc. (NASDAQ:BEAT) shareholders are probably generally happy, the stock hasn’t had particularly good run recently, with the share price falling 14% in the last quarter. But that doesn’t undermine the fantastic longer term performance (measured over five years). In that time, the share price has soared some 601% higher! Arguably, the recent fall is to be expected after such a strong rise. But the real question is whether the business fundamentals can improve over the long term.

Anyone who held for that rewarding ride would probably be keen to talk about it.

See our latest analysis for BioTelemetry

To quote Buffett, ‘Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace…’ One way to examine how market sentiment has changed over time is to look at the interaction between a company’s share price and its earnings per share (EPS).

During the five years of share price growth, BioTelemetry moved from a loss to profitability. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here. Since the company was unprofitable five years ago, but not three years ago, it’s worth taking a look at the returns in the last three years, too. We can see that the BioTelemetry share price is up 160% in the last three years. Meanwhile, EPS is up 51% per year. This EPS growth is higher than the 38% average annual increase in the share price over the same three years. So you might conclude the market is a little more cautious about the stock, these days.

NasdaqGS:BEAT Past and Future Earnings, July 17th 2019
NasdaqGS:BEAT Past and Future Earnings, July 17th 2019

It is of course excellent to see how BioTelemetry has grown profits over the years, but the future is more important for shareholders. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

A Different Perspective

BioTelemetry shareholders are down 4.6% for the year, but the market itself is up 6.4%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 48% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. Before deciding if you like the current share price, check how BioTelemetry scores on these 3 valuation metrics.

But note: BioTelemetry may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.